Security
Sunshine Biopharma Inc. Warrant · SBFMW
SBFMWNASDAQWarrantCurrentCIK 1402328Updated Oct 15, 2026
Name history
Sunshine Biopharma, Inc · through Oct 17, 2024Mountain West Business Solutions, Inc · through Nov 2, 2009mountain west business solutions,inc · through Oct 19, 2007mountain state business solutions,inc · through May 25, 2007
SBFMW price & chart
Loading TradingView…
NASDAQ:SBFMW on TradingView ↗About the company
We are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries: (i) Nora Pharma Inc., a Canadian corporation, through which we currently have 60 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc., a Canadian corporation through which we develop and sell OTC supplements.
In the news
No coverage from other publishers is available.
Recent filings
PRE 14C filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B4 filing
EFFECT filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 31,487,379Source | 30,056,816Source | 33,632,901Source | 31,965,250Source | 29,300,978Source | 27,930,375Source | 29,187,105Source | 31,898,717Source | 30,079,167Source | 30,560,392Source | 27,346,961Source | 29,243,848Source |
| Property, Plant and Equipment, NetUSD | 598,087Source | 590,801Source | 477,047Source | 638,354Source | 541,410Source | 516,349Source | 519,787Source | 401,642Source | 557,370Source | 546,055Source | 365,868Source | 394,249Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 2,009,337Source | 2,942,684Source | 1,841,970Source | 2,490,827Source | 2,447,128Source | 1,917,812Source | 3,193,214Source | 2,065,603Source | 1,889,370Source | 3,019,717Source | 1,444,259Source | 776,856Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | — | — | — | — | — | — | — | — | 21,826,437Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 4,155,599Source | 3,218,682Source | 4,035,360Source | 3,587,560Source | 3,973,550Source | 4,011,632Source | 3,445,242Source | 2,827,720Source | 3,459,864Source | 3,868,418Source | 2,552,362Source | 1,912,153Source |
| Inventory, NetUSD | 14,063,706Source | 9,820,730Source | 12,121,796Source | 13,018,702Source | 8,490,745Source | 13,168,430Source | 11,857,135Source | 7,697,906Source | 13,472,025Source | 11,278,105Source | 5,734,755Source | 3,289,945Source |
| Assets, CurrentUSD | 27,967,232Source | 25,981,863Source | 30,665,427Source | 27,851,018Source | 25,748,520Source | 24,783,176Source | 24,480,980Source | 28,831,224Source | 26,853,581Source | 25,966,349Source | 24,890,055Source | 27,312,334Source |
| Operating Lease, Right-of-Use AssetUSD | 820,489Source | 541,468Source | 648,457Source | 892,817Source | 563,920Source | 713,038Source | 900,890Source | 600,248Source | 778,846Source | 936,037Source | 646,779Source | 760,409Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 7,288,023Source | 5,017,504Source | 6,094,899Source | 6,280,446Source | 5,811,114Source | 6,413,781Source | 6,484,635Source | 7,079,102Source | 7,040,707Source | 7,059,638Source | 6,139,600Source | 7,616,278Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 13,000Source | 13,000Source | 13,000Source | 13,000Source | 13,000Source | 13,000Source | 13,000Source | 13,000Source | 13,000Source | 13,000Source | 1,000Source | 1,000Source |
| Common Stock, Value, IssuedUSD | 4,555Source | 2,000Source | 2,389Source | 4,555Source | 1,171Source | 4,905Source | 2,707Source | 995Source | 4,905Source | 2,580Source | 28,024Source | 22,585Source |
| Additional Paid in CapitalUSD | 97,376,841Source | 91,737,284Source | 106,004,591Source | 97,376,841Source | 89,842,503Source | 98,100,990Source | 93,710,078Source | 89,842,680Source | 98,100,990Source | 93,354,907Source | 84,387,890Source | 80,841,752Source |
| Retained Earnings (Accumulated Deficit)USD | -72,874,199Source | -66,881,562Source | -77,823,043Source | -71,990,379Source | -65,683,759Source | -76,258,995Source | -70,219,545Source | -65,189,459Source | -75,015,126Source | -69,039,774Source | -63,905,658Source | -59,399,614Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -320,841Source | 168,590Source | -658,935Source | 280,787Source | -683,050Source | -343,306Source | -803,770Source | 152,400Source | -65,309Source | -829,959Source | 696,105Source | 161,847Source |
| Stockholders' Equity Attributable to ParentUSD | 24,199,356Source | 25,039,312Source | 27,538,002Source | 25,684,804Source | 23,489,865Source | 21,516,594Source | 22,702,470Source | 24,819,615Source | 23,038,460Source | 23,500,754Source | 21,207,361Source | 21,627,570Source |
| Liabilities and EquityUSD | 31,487,379Source | 30,056,816Source | 33,632,901Source | 31,965,250Source | 29,300,978Source | 27,930,375Source | 29,187,105Source | 31,898,717Source | 30,079,167Source | 30,560,392Source | 27,346,961Source | 29,243,848Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,651,315Source | 4,528,477Source | 5,619,079Source | 5,573,916Source | 5,299,478Source | 5,878,167Source | 5,762,436Source | 6,533,405Source | 6,443,922Source | 6,314,914Source | 5,551,836Source | 6,931,014Source |
| Operating Lease, Liability, CurrentUSD | 218,053Source | 116,253Source | 202,518Source | 222,496Source | 114,452Source | 209,226Source | 213,983Source | 115,398Source | 215,637Source | 207,756Source | 118,670Source | 123,026Source |
| Accounts Payable, CurrentUSD | 6,137,465Source | 4,157,253Source | 4,852,488Source | 4,797,465Source | 4,930,055Source | 5,104,868Source | 5,024,541Source | 3,615,205Source | 5,664,212Source | 5,543,085Source | 2,585,466Source | 2,802,796Source |
| Operating Lease, Liability, NoncurrentUSD | 636,708Source | 440,298Source | 475,820Source | 706,530Source | 462,906Source | 535,614Source | 722,199Source | 496,968Source | 596,785Source | 744,724Source | 539,035Source | 642,232Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 389,513Source | 225,491Source | 344,325Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 76,859Source | 64,793Source | 332,070Source | 223,527Source | 149,147Source | 25,163Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 609,601Source | -426,673Source | 116,173Source | 2,338,195Source | 594,141Source | 524,486Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -78,399Source | 568,834Source | 1,637,277Source | 6,006,864Source | 2,365,549Source | -42,983Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 94,939Source | -144,474Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,072,100Source | -1,695,002Source | -5,331,073Source | -12,531,180Source | -8,775,111Source | -5,248,358Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -104,518Source | -212,017Source | -836,306Source | -2,320,847Source | -656,150Source | -14,619,390Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 5,129Source | 7,490Source | 174,491Source | 1,657,055Source | 82,251Source | 193,982Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | 0Source | 0Source | 3,139,651Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 0Source | 355,297Source | 4,748,408Source | 9,289,507Source | 3,425,587Source | 39,465,107Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 9,306,438Source | 12,206,655Source | 13,748,301Source | 10,305,320Source | 6,913,013Source | 8,124,610Source | 9,123,308Source | 9,686,529Source | 16,292,347Source | 21,826,437Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | 0Source | 48,287Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 582,483Source | — | 0Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -33,677Source | -10,197Source | — | 0Source | -62,674Source | -1,075Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 37,758Source | 77,009Source | — | — |
| DepreciationUSD | — | — | 95,821Source | 64,627Source | — | 72,533Source | — | 64,793Source | 176,346Source | 146,518Source | 110,701Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 253Source | 15,153Source | -6Source | 1,940Source | -18Source | 451Source | 2,642Source | -44,082Source | -245Source | -476Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | — | — | -10,250Source | 0Source | — | — | — | — | -10,257Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 4,160,153Source | 3,972,504Source | 4,039,540Source | 5,477,521Source | 3,576,587Source | 4,026,176Source | 18,482,706Source | 16,481,915Source | 13,124,470Source | 28,697,325Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | 554,650Source | 0Source | — | 1,061,809Source | — | — | 1,748,247Source | — | — | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 18,326,719Source |
| Income Tax Expense (Benefit)USD | — | — | -137,438Source | 215,217Source | 0Source | -209,166Source | 0Source | -40,161Source | 21,609Source | -234,858Source | 395,166Source | 233,304Source |
| Induced Conversion of Convertible Debt ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | 8,774Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -883,820Source | -1,197,803Source | -1,564,048Source | -1,770,834Source | -1,243,869Source | -1,179,771Source | -5,975,352Source | -5,134,116Source | -4,506,044Source | -26,744,440Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -1,197,803Source | — | — | -1,243,869Source | -1,179,771Source | -5,975,352Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 65,355Source | 123,767Source | 48,810Source | 74,655Source | 151,728Source | 75,818Source | 273,286Source | 443,147Source | 674,421Source | 489,614Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | 1,828,596Source | 8,522,411Source | 4,089,218Source | 30,367,185Source |
| Impairment of Intangible Assets (Excluding Goodwill) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Impairment of Intangible Assets, Finite-lived | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 9,417,179Source | 8,435,178Source | 9,263,687Source | 9,410,230Source | 8,088,765Source | 8,901,341Source | 36,305,891Source | 34,874,283Source | 24,092,787Source | 4,345,603Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -1,086,613Source | -1,106,353Source | -1,612,858Source | -2,054,655Source | -1,395,597Source | -1,295,750Source | -6,227,029Source | -5,812,121Source | -4,785,299Source | -27,000,750Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -1,021,258Source | -982,586Source | -1,564,048Source | -1,980,000Source | -1,243,869Source | -1,219,932Source | -5,953,743Source | -5,368,974Source | -4,110,878Source | -26,511,136Source |
| Income Tax Expense (Benefit)USD | — | — | -137,438Source | 215,217Source | 0Source | -209,166Source | 0Source | -40,161Source | 21,609Source | -234,858Source | 395,166Source | 233,304Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -883,820Source | -1,197,803Source | -1,564,048Source | -1,770,834Source | -1,243,869Source | -1,179,771Source | -5,975,352Source | -5,134,116Source | -4,506,044Source | -26,744,440Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.19Source | -0.94Source | -1.15Source | -3.94Source | -0.25Source | -0.44Source | -1.44Source | -7.32Source | -0.19Source | -1.76Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | — | -0.82Source | — | -0.44Source | — | -7.32Source | -0.19Source | -1.76Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 4,555,945Source | 1,267,565Source | 1,365,324Source | 449,611Source | 4,905,945Source | 2,703,293Source | 4,157,086Source | 701,749Source | 24,331,908Source | 15,180,868Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | 1,267,565Source | — | 3,604,653Source | — | 2,703,293Source | — | 701,749Source | 24,331,908Source | 15,180,868Source |
| Interest Expense (non-operating)USD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | 8,774Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 37,758Source | 77,009Source | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | 77,974Source | 72,533Source | — | — | — | — | 149,147Source | 25,163Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 253Source | 15,153Source | -6Source | 1,940Source | -18Source | 451Source | 2,642Source | -44,082Source | -245Source | -476Source |
| General and Administrative ExpenseUSD | — | — | 4,160,153Source | 3,972,504Source | 4,039,540Source | 5,477,521Source | 3,576,587Source | 4,026,176Source | 18,482,706Source | 16,481,915Source | 13,124,470Source | 28,697,325Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 18,326,719Source |
| Gross ProfitUSD | — | — | 3,073,540Source | 2,866,151Source | 2,426,682Source | 3,422,866Source | 2,180,990Source | 2,730,426Source | 12,255,677Source | 10,669,794Source | 8,339,171Source | 1,696,575Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 1,250,286Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 137,308Source | 39,412Source |
| Interest Income, Debt Securities, OperatingUSD | — | — | 75,352Source | 108,614Source | — | 72,715Source | 48,426Source | 75,367Source | 280,901Source | 496,003Source | 811,974Source | 518,650Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -1,197,803Source | — | — | -1,243,869Source | -1,179,771Source | -5,975,352Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 65,355Source | 123,767Source | 48,810Source | 74,655Source | 151,728Source | 75,818Source | 273,286Source | 443,147Source | 674,421Source | 489,614Source |
| Other General and Administrative ExpenseUSD | — | — | 614,661Source | 530,334Source | 762,187Source | 806,605Source | 871,608Source | 925,878Source | 3,864,584Source | 3,110,026Source | — | — |
| Research and Development ExpenseUSD | — | — | 119,298Source | 126,362Source | 13,222Source | 196,232Source | 31,724Source | 215,277Source | 604,308Source | 933,902Source | 1,855,830Source | 811,858Source |
| Other Income | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Taxes, Miscellaneous | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-299274
- Gross proceeds
- 6000000.0
- Net proceeds
- 5579995.44
- Deal price
- 0.55
- Shares
- 10909091
- Offering amount
- $6,000,000
- Offering price
- $0.55
- Ticker
- SBFM
Underwriters: Aegis Capital Corp.
Registration 333-298626
Registration 333-295800
- Gross proceeds
- 6000000.0
- Net proceeds
- 5580000.0
- Deal price
- 0.5
- Shares
- 12000000
- Offering amount
- $6,000,000
- Offering price
- $0.50
- Ticker
- SBFM
Underwriters: Aegis Capital Corp.
Registration 333-289230
Filing attachments
sunshine_ex107.htm · S-1 · 2026-10-02
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Sunshine Biopharma Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price …
Read attachment ↗sunshine_ex107.htm · S-1 · 2026-08-28
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Sunshine Biopharma Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗sunshine_ex107.htm · S-1 · 2026-05-12
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Sunshine Biopharma Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price …
Read attachment ↗sunshine_ex107.htm · S-1 · 2025-08-05
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Sunshine Biopharma Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗